StudyTeam for Sites Reaches 10,000 Global Research Sites, Streamlining Clinical Trials

What You Should Know:

– OneStudyTeam, a member of the Reify Health portfolio, provides the cloud-based software platform StudyTeam to accelerate the development of new and life-saving therapies. StudyTeam brings research site workflows online and enables sites, sponsors, and other key stakeholders to work together more effectively using common technology.

–  The suite of StudyTeam solutions reduces site burden and helps sites pre-screen and enroll more patients, provides sponsors with end-to-end visibility into recruitment activity across all channels, and guides sites in conducting the trial for patients who have been enrolled.

OneStudyTeam Announces Global Adoption of StudyTeam for Sites, Enhancing Clinical Trial Efficiency

OneStudyTeam, the developer of the patient enrollment management platform StudyTeam, has announced that over 10,000 research sites worldwide are now utilizing StudyTeam for Sites. This platform, available in 15 languages, provides digital workflow tools that enhance various aspects of clinical trial management, including:

– Recruitment and Enrollment Management: Streamlining processes for improved efficiency.

– Source Data Collection: Facilitating accurate and timely data capture.

Financial Management: Managing budgets and generating invoices seamlessly.

Each team member at these sites can select their preferred language while managing clinical trial pipelines and patient databases. Furthermore, research sites and their local sponsor teams can access training materials in 23 languages, including English, Spanish, Mandarin, Bulgarian, and Portuguese.

The impact of StudyTeam for Sites on workflow efficiency is significant. For instance, Seacoast Kidney & Hypertension Specialists in New Hampshire, after implementing the eSource solution within StudyTeam, reported:

– A 25-minute reduction in patient visit times.

– A 50% decrease in monitoring corrections for source data capture.

Prior to adopting StudyTeam’s eSource solution, staff at Seacoast Kidney & Hypertension Specialists typically spent 45 minutes on each patient visit.

In addition to the United States, over 200 clinical research sites in 13 other countries are using StudyTeam, including Argentina, Brazil, Canada, France, Italy, India, Japan, Mexico, Poland, Spain, and the United Kingdom. Notably, more than 400 sites in South Korea and Turkey have also adopted this software.

StudyTeam facilitates secure connections between sites and their trial sponsors, enabling automatic and effortless data sharing. This feature alleviates burdens on research sites while enhancing sponsors’ ability to identify and address recruitment and enrollment barriers before timelines are compromised.

Another vital functionality of StudyTeam is the ability to create a filterable database of potential candidates across trials. Research coordinators can efficiently filter candidates based on research indication, eligibility criteria, and other relevant factors, ensuring optimal patient-trial matching.

Recognizing the potential burden that additional technology may impose on site workflows, OneStudyTeam has recently launched an online learning portal. The StudyTeam Learning Center allows site teams to familiarize themselves with the system at their convenience and pace.

By offering intuitive workflow tools and providing sponsors with streamlined enrollment insights, OneStudyTeam aims to accelerate clinical trial enrollment, ultimately expediting the delivery of therapies to market. For more information on StudyTeam solutions, visit OneStudyTeam.com.

“We are using StudyTeam to store patients to see if they are eligible for the study later on,” said Dr. Elise Jonasson Nielsen, who works at the department of hepatology and gastroenterology at the Esbjerg Hospital, University Hospital of Southern Denmark. “[In clinical research] it can be difficult to find the patients that are a fit for the study…. But that is the main reason we are using StudyTeam; it gives us an overview and we all can comment in the portal.”